Can the IL6 rs1800795 CG genotype alter inflammatory and acute-phase responses?

The IL6 rs1800795 (−174 G>C) single nucleotide polymorphism (SNP) is a functional regulatory variant that plays a critical role in modulating the human body’s systemic inflammatory response to immunological stress.

Mechanistic pathways of IL-6 regulation

• The rs1800795 SNP, located in the proximal promoter region of the IL6 gene, directly gates transcription factor access to the DNA.
• Specifically, this genetic variation alters the binding capability and accessibility of key transcription factors, including GATA1 and Smad4.
• The heterozygous CG genotype exhibits intermediate-to-high basal and inducible promoter activity, frequently grouping with the high-producing GG genotype. This alters the overall rate of IL-6 gene transcription in a highly cell- and stimulus-dependent manner.

Trigger-induced acute-phase responses

• When immune triggers—such as surgical stress, pathogens (like LPS), or pro-inflammatory cytokines (like IL-1)—are present, they interact with the genetically determined inflammatory pathway.
• The altered IL-6 production dynamically drives downstream hepatic acute-phase responses.
• Consequently, heightened systemic inflammatory responsiveness triggers a marked upward shift in serum ferritin, which acts as a positive acute-phase reactant.
• Simultaneously, this inflammatory signaling downregulates hepatic protein synthesis, leading to a corresponding downward shift in serum albumin, a canonical negative acute-phase reactant.

Bottom line

• Bottom line: The IL6 rs1800795 CG genotype functionally alters transcription factor binding (such as GATA1 and Smad4) to modulate IL-6 transcription, making individuals harboring this variant highly susceptible to significant upward shifts in serum ferritin and downward shifts in serum albumin when active immune triggers are present.